100 mg AP1189

( DrugBank: - / KEGG DRUG: - )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	6

告示番号	疾患名（ページ内リンク）	臨床試験数
222	一次性ネフローゼ症候群	3

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

trials per page:

Showing 1 to 6 of 6 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05604885 (ClinicalTrials.gov)	November 30, 2022	31/10/2022	A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients Wi ...	A Two-part, Randomized, Double-blind, Multi-center, Placebo-controlled Study of the Dose-range, Safe ...	Rheumatoid Arthritis	Drug: AP1189, 60 mg;Drug: AP1189, 80 mg;Drug: AP1189, 100 mg;Drug: Placebo	SynAct Pharma Aps	NBCD A/S	Recruiting	18 Years	85 Years	All	420	Phase 2	Moldova, Republic of
2	NCT05516979 (ClinicalTrials.gov)	September 26, 2022	24/8/2022	A Safety & Efficacy Study of Treatment With AP1189in Rheumatoid Arthritis Patients naïve to DMARD Tr ...	A Double-blind, Multi-center, Randomized, Placebo-controlled Study of the Safety and Efficacy of 12 ...	Rheumatoid Arthritis	Drug: 100 mg AP1189;Drug: Placebo	SynAct Pharma Aps	NBCD A/S	Recruiting	18 Years	85 Years	All	120	Phase 2	Moldova, Republic of
3	EUCTR2019-001185-15-BG (EUCTR)	29/05/2020	15/05/2020	A double blind trial in two parts in people with active newly discovered rheumatoid arthritis. The e ...	A double-blind, multi-center, two-part, randomized, placebo-controlled study of the safety, tolerabi ...	rheumatoid arthritis MedDRA version: 23.1;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Product Code: AP1189 INN or Proposed INN: Not applicable	SynAct Pharma ApS	NULL	Not Recruiting			Female: yes Male: yes	135	Phase 2	Denmark;Bulgaria;Norway;Moldova, Republic of;Sweden
4	EUCTR2019-001185-15-NO (EUCTR)	19/02/2020	07/11/2019	A double blind trial in two parts in people with active newly discovered rheumatoid arthritis. The e ...	A double-blind, multi-center, two-part, randomized, placebo-controlled study of the safety, tolerabi ...	rheumatoid arthritis MedDRA version: 23.1;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Product Code: AP1189 INN or Proposed INN: Not applicable	SynAct Pharma ApS	NULL	Not Recruiting			Female: yes Male: yes	135	Phase 2	Denmark;Bulgaria;Norway;Moldova, Republic of;Sweden
5	EUCTR2019-001185-15-SE (EUCTR)	06/11/2019	01/07/2019	A double blind trial in two parts in people with active newly discovered rheumatoid arthritis. The e ...	A double-blind, multi-center, two-part, randomized, placebo-controlled study of the safety, tolerabi ...	rheumatoid arthritis MedDRA version: 23.1;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Product Code: AP1189 INN or Proposed INN: Not applicable	SynAct Pharma ApS	NULL	Not Recruiting			Female: yes Male: yes	135	Phase 2	Denmark;Bulgaria;Norway;Moldova, Republic of;Sweden
6	EUCTR2019-001185-15-DK (EUCTR)	06/06/2019	12/04/2019	A double-blind, multi-center, two-part, randomized, placebo-controlled study of the safety, tolerabi ...	A double-blind, multi-center, two-part, randomized, placebo-controlled study of the safety, tolerabi ...	rheumatoid arthritis MedDRA version: 23.1;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Product Code: AP1189 INN or Proposed INN: Not applicable	SynAct Pharma ApS	NULL	Not Recruiting			Female: yes Male: yes	135	Phase 2	Denmark;Bulgaria;Norway;Moldova, Republic of;Sweden

First Previous1Next Last

222. 一次性ネフローゼ症候群

臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194

trials per page:

Showing 1 to 3 of 3 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-000971-18-NO (EUCTR)	28/06/2021	23/02/2021	A double-blind study for patients with idiopathic membranous nephropathy in treatment with ACE inhib ...	An exploratory, randomized, double-blind, multicenter, placebo-controlled study to assess the safety ...	Idiopathic membranous nephropathy MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: ...	Product Code: AP1189 INN or Proposed INN: Not applicable	SynAct Pharma ApS	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	18	Phase 2	Denmark;Norway
2	NCT04456816 (ClinicalTrials.gov)	August 31, 2020	24/6/2020	A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189in Patien ...	An Exploratory, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Assess the Safety ...	Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy;Severe Proteinuria Due to Idiopathic Mem ...	Drug: 100 mg AP1189;Drug: Placebo	SynAct Pharma Aps	NULL	Recruiting	18 Years	85 Years	All	23	Phase 2	Denmark
3	EUCTR2020-000971-18-DK (EUCTR)	28/05/2020	04/04/2020	A double-blind study for patients with idiopathic membranous nephropathy in treatment with ACE inhib ...	An exploratory, randomized, double-blind, multicenter, placebo-controlled study to assess the safety ...	Idiopathic membranous nephropathy MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: ...	Product Code: AP1189 INN or Proposed INN: Not applicable	SynAct Pharma ApS	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	18	Phase 2	Denmark

First Previous1Next Last